^
    1d
    Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer (clinicaltrials.gov)
    P2, N=15, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting | Trial completion date: Jun 2026 --> Dec 2026 | Trial primary completion date: Jan 2026 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    1d
    CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Jan 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    CXCL8 (Chemokine (C-X-C motif) ligand 8)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • Cdactin-O (CBM588)
    1d
    Metformin Hydrochloride in Combination With Standard of Care Systemic Therapy in Previously Untreated Advanced Unresectable or Metastatic Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Not yet recruiting --> Recruiting
    Enrollment open
    2d
    Assessment of Healing and Function After Reconstruction Surgery for Bone Sarcomas (clinicaltrials.gov)
    P=N/A, N=300, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    2d
    A Single-Arm Study on the Efficacy of Sequential Chemoradiotherapy Followed by Surgery in Adult Nasal and Paranasal Sinus Rhabdomyosarcoma (clinicaltrials.gov)
    P=N/A, N=43, Enrolling by invitation, Eye & ENT Hospital of Fudan University
    New trial
    |
    cisplatin • cyclophosphamide • epirubicin
    2d
    Case report: Primary pulmonary rhabdomyosarcoma exhibiting epithelial morphology and unusual immunophenotype - A significant diagnostic pitfall. (PubMed, Respir Med Case Rep)
    We herein elaborate on these findings to enhance clinical awareness and facilitate accurate diagnosis in future cases. To the best of our knowledge, To the best of our knowledge, this is the first reported case of epithelioid rhabdomyosarcoma demonstrating diffuse and strong nuclear TTF-1 immunoreactivity across two distinct antibody clones.
    Journal
    |
    NCAM1 (Neural cell adhesion molecule 1) • NKX2-1 (NK2 Homeobox 1) • MYOD1 (Myogenic Differentiation 1)
    2d
    Giant malignant peripheral nerve sheath tumor: Illustrative case and surgical technique. (PubMed, Surg Neurol Int)
    The benefits - including the emotional ones - can be so significant that, despite their malignant lineage, resection and regrowth control remain worthwhile for as long as possible. Four- or six-hand surgery for these tumors can reduce bleeding, operative time, and complications.
    Journal
    |
    NF1 (Neurofibromin 1)
    2d
    Histone deacetylases: Function in tumor development and therapeutic prospects (Review). (PubMed, Oncol Lett)
    Furthermore, the present review discussed recent progress in structural modifications aimed at enhancing selectivity while reducing toxicity, as well as novel targeting strategies. Concluding with perspectives on HDAC-based therapies, the present review underscores the key importance of precision targeting and combinatorial approaches to improve patient outcomes in the future.
    Review • Journal
    |
    HDAC11 (Histone Deacetylase 11) • HDAC5 (Histone Deacetylase 5) • HDAC3 (Histone Deacetylase 3) • HDAC7 (Histone Deacetylase 7)
    2d
    LncRNA-PRLB drives ovarian cancer progression and chemoresistance by stabilizing GPX4 mRNA through the FUS-mediated suppression of ferroptosis. (PubMed, Front Med (Lausanne))
    Ovarian cancer is highly lethal, largely due to the rapid development of paclitaxel resistance...RNA pull-down, RNA immunoprecipitation (RIP), and actinomycin D mRNA decay assays were conducted to elucidate the molecular interactions between lncRNA-PRLB, the RNA-binding protein fused in sarcoma (FUS), and glutathione peroxidase 4 (GPX4) mRNA...This study identifies lncRNA-PRLB as a critical upstream regulator of ferroptosis resistance and chemoresistance in ovarian cancer. By scaffolding FUS to stabilize GPX4 mRNA, lncRNA-PRLB maintains GPX4 expression and enables tumor cells to evade ferroptotic cell death.
    Journal
    |
    CASP3 (Caspase 3) • GPX4 (Glutathione Peroxidase 4) • FUS (FUS RNA Binding Protein)
    |
    paclitaxel • dactinomycin
    2d
    Breathless and Beyond: Anterior Mediastinal Malignant Peripheral Nerve Sheath Tumor as a Rare Neurofibromatosis Type 1 Manifestation. (PubMed, Clin Case Rep)
    Multidisciplinary evaluation, including biopsy and imaging, is essential for diagnosis, with surgical resection as the primary treatment. Early recognition and vigilant monitoring in NF1 patients are crucial for prompt intervention and improved outcomes.
    Journal
    |
    NF1 (Neurofibromin 1)
    2d
    Epstein-Barr Virus-Positive Inflammatory Follicular Dendritic Cell Sarcoma Occurring in Spleen of a Patient after Chemotherapy for Lung Carcinoma: A Case Report. (PubMed, Case Rep Oncol)
    Based on these findings, the splenic lesion was diagnosed as EBV+ inflammatory FDCS. The present case might provide information to discuss the possible pathogenesis of EBV+ inflammatory FDCS in the context of immunosuppression.
    Journal
    |
    FCER2 (Fc Fragment Of IgE Receptor II)
    2d
    CALySSEY: CD70.CAR for CD70+ Lymphoma, Myeloma and Solid Tumors (clinicaltrials.gov)
    P1, N=88, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026
    Trial initiation date